Skip to content
2000
Volume 21, Issue 8
  • ISSN: 1573-4110
  • E-ISSN: 1875-6727

Abstract

Introduction

Leishmaniasis is a disease caused by the Leishmania protozoa, with Cutaneous Leishmaniasis (CL) being the most common form of the illness. Paromomycin (PM) has recently garnered increased interest for its effectiveness against Leishmania, but it is hindered by limited efficacy, low oral bioavailability, and rapid clearance. As far as we know, there have been no studies examining the impact of nano lecithin-chitosan-containing paromomycin (Nano-PM) on CL. Therefore, the objective of the present study was to create Nano-PM and assess its effects on the promastigotes and on the lesions caused by in the BALB/c mice model .

Methods

The loading of PM into lecithin-chitosan nanoparticles was achieved using the ionic gelation method, and the resulting nanoparticles were characterized. The IC values for PM, Glucantim, and Nano-PM against promastigotes were determined after 24, 48, and 72 hours of treatment. The viability of promastigotes was assessed using the MTT assay. The Nano-PM formulation was administered local treatment to mice for a period of 28 days, during which lesion sizes were measured weekly. Furthermore, the parasite load in the infected mice was quantified using quantitative real-time polymerase chain reaction (qPCR).

Results

IC of Nano-PM was significantly lower than Glucantim ( < 0.0001 after24 h incubation, = 0.013 for 48h and < 0.0001 for 72 h) and PM ( < 0.0001 after24 h, = 0.003 for 48h and < 0.0001 for 72h). All concentrations of Nano-PM had the highest toxicity on promastigotes in comparison with other groups after 24, 48, and 72 h treatment. Moreover, a significant reduction in the lesion size was found in the Nano-PM group in comparison with the control group after three ( = 0.0369) and four ( = 0.0009) weeks of treatment. More importantly, Nano-PM significantly reduced the parasite load compared to the control and the lecithin-chitosan groups ( = 0.001 for both).

Conclusion

Our findings showed that Nano-PM had lower toxicity (lower IC) on promastigotes compared to Glucantim and PM. Moreover, Nano-PM treated mice showed reduced lesion size compared to the control group. Additionally, Nano-PM led to a significant decrease in parasite burden compared to the control group and the lecithin-chitosan group. Nevertheless, more complementary research is needed to approve our findings.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cac/10.2174/0115734110314300240723050137
2025-07-29
2025-12-24

  • From This Site

    /content/journals/cac/10.2174/0115734110314300240723050137
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KhanM.M. ZaidiS.S. SiyalF.J. KhanS.U. IshratG. BatoolS. MustaphaO. KhanS. DinF. Statistical optimization of co-loaded rifampicin and pentamidine polymeric nanoparticles for the treatment of cutaneous leishmaniasis.J. Drug Deliv. Sci. Technol.20237910400510.1016/j.jddst.2022.104005
     [Google Scholar]
  2. SantanaÉ.S. BelmiroV.B.S. de SiqueiraL.B.O. do NascimentoT. Santos-OliveiraR. dos Santos MatosA.P. Ricci-JuniorE. Nanotechnology as an alternative to improve the treatment of cutaneous leishmaniasis: A systematic review of the literature.J. Drug Deliv. Sci. Technol.20227510362210.1016/j.jddst.2022.103622
     [Google Scholar]
  3. Torres-GuerreroE. Quintanilla-CedilloM.R. Ruiz-EsmenjaudJ. ArenasR. Leishmaniasis: a review.F1000 Res.2017675010.12688/f1000research.11120.1 28649370
     [Google Scholar]
  4. ReithingerR. DujardinJ.C. LouzirH. PirmezC. AlexanderB. BrookerS. Cutaneous leishmaniasis.Lancet Infect. Dis.20077958159610.1016/S1473‑3099(07)70209‑8 17714672
     [Google Scholar]
  5. YardleyV. KhanA.A. MartinM.B. SliferT.R. AraujoF.G. MorenoS.N.J. DocampoR. CroftS.L. OldfieldE. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii.Antimicrob. Agents Chemother.200246392993110.1128/AAC.46.3.929‑931.2002 11850291
     [Google Scholar]
  6. SinghS. SivakumarR. Challenges and new discoveries in the treatment of leishmaniasis.J. Infect. Chemother.200410630731510.1007/s10156‑004‑0348‑9 15614453
     [Google Scholar]
  7. FernándezM.M. MalchiodiE.L. AlgranatiI.D. Differential effects of paromomycin on ribosomes of Leishmania mexicana and mammalian cells.Antimicrob. Agents Chemother.2011551869310.1128/AAC.00506‑10 20956601
     [Google Scholar]
  8. KhalilE.A. AlkawareekM.Y. OthmanG. TbakhiB. Al-BakriA.G. Evaluation of paromomycin sulphate permeation using ex vivo human skin model.Pharm. Dev. Technol.201924339039310.1080/10837450.2018.1485697 29873575
     [Google Scholar]
  9. CroftS.L. OlliaroP. Leishmaniasis chemotherapy—challenges and opportunities.Clin. Microbiol. Infect.201117101478148310.1111/j.1469‑0691.2011.03630.x 21933306
     [Google Scholar]
  10. YasinzaiM. KhanM. NadhmanA. ShahnazG. Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives.Future Med. Chem.20135151877188810.4155/fmc.13.143 24144417
     [Google Scholar]
  11. Gutiérrez-MéndezN. Chavez-GarayD.R. Leal-RamosM.Y. Lecithins: A comprehensive review of their properties and their use in formulating microemulsions.J. Food Biochem.2022467e1415710.1111/jfbc.14157 35355280
     [Google Scholar]
  12. RiezkA. Van BocxlaerK. YardleyV. MurdanS. CroftS.L. Activity of amphotericin B-loaded chitosan nanoparticles against experimental cutaneous leishmaniasis.Molecules20202517400210.3390/molecules25174002 32887341
     [Google Scholar]
  13. QiaoY. BaiX.F. DuY.G. Chitosan oligosaccharides protect mice from LPS challenge by attenuation of inflammation and oxidative stress.Int. Immunopharmacol.201111112112710.1016/j.intimp.2010.10.016 21059391
     [Google Scholar]
  14. GuthaY. PathakJ.L. ZhangW. ZhangY. JiaoX. Antibacterial and wound healing properties of chitosan/poly(vinyl alcohol)/zinc oxide beads (CS/PVA/ZnO).Int. J. Biol. Macromol.201710323424110.1016/j.ijbiomac.2017.05.020 28499948
     [Google Scholar]
  15. BruniN. StellaB. GiraudoL. Della PepaC. GastaldiD. DosioF. Nanostructured delivery systems with improved leishmanicidal activity: a critical review.Int. J. Nanomedicine2017125289531110.2147/IJN.S140363 28794624
     [Google Scholar]
  16. HojatizadeM. SoleymaniM. TafaghodiM. BadieeA. ChavoshianO. JaafariM.R. Chitosan nanoparticles loaded with whole and soluble leishmania antigens, and evaluation of their immunogenecity in a mouse model of leishmaniasis.Iran. J. Immunol.2018154281293 30593742
     [Google Scholar]
  17. CabralF.V. PelegrinoM.T. SeabraA.B. RibeiroM.S. Nitric-oxide releasing chitosan nanoparticles towards effective treatment of cutaneous leishmaniasis.Nitric Oxide2021113-114313810.1016/j.niox.2021.04.008 33940194
     [Google Scholar]
  18. EsfandiariF. MotazedianM.H. AsgariQ. MorowvatM.H. MolaeiM. HeliH. Paromomycin-loaded mannosylated chitosan nanoparticles: Synthesis, characterization and targeted drug delivery against leishmaniasis.Acta Trop.201919710507210.1016/j.actatropica.2019.105072 31300160
     [Google Scholar]
  19. EsfandiariF. HeliH. AsgariQ. MorowvatM.H. BarazeshA. GoudarziF. Paromomycin-Loaded Mannosylated Chitosan Nanoparticles: Targeted Drug Delivery Against BALB/c Mice Infected To L.Major2021
     [Google Scholar]
  20. MorenoE. SchwartzJ. LarreaE. CondeI. FontM. SanmartínC. IracheJ.M. EspuelasS. Assessment of β-lapachone loaded in lecithin-chitosan nanoparticles for the topical treatment of cutaneous leishmaniasis in L. major infected BALB/c mice.Nanomedicine20151182003201210.1016/j.nano.2015.07.011 26282379
     [Google Scholar]
  21. JainA. ThakurK. SharmaG. KushP. JainU.K. Fabrication, characterization and cytotoxicity studies of ionically cross-linked docetaxel loaded chitosan nanoparticles.Carbohydr. Polym.2016137657410.1016/j.carbpol.2015.10.012 26686106
     [Google Scholar]
  22. Ribeiro AntinarelliL.M. GlanzmannN. MendonçaD.V.C. LageD.P. Oliveira-da-SilvaJ.A. TavaresG.S.V. CarvalhoA.M.R.S. FreitasC.S. MartinsV.T. DuarteM.C. Menezes-SouzaD. da SilvaA.D. CoelhoE.A.F. Soares CoimbraE. Parasitological and immunological evaluation of a quinoline derivative salt incorporated into a polymeric micelle formulation against Leishmania infantum infection.Parasitol. Res.202212172129214010.1007/s00436‑022‑07544‑1 35614147
     [Google Scholar]
  23. DavoudiM. JadidiY. MoayediK. FarrokhiV. AfrishamR. Ameliorative impacts of polymeric and metallic nanoparticles on cisplatin-induced nephrotoxicity: a 2011–2022 review.J. Nanobiotechnology202220150410.1186/s12951‑022‑01718‑w 36457031
     [Google Scholar]
  24. KipA.E. SchellensJ.H.M. BeijnenJ.H. DorloT.P.C. Clinical pharmacokinetics of systemically administered antileishmanial drugs.Clin. Pharmacokinet.201857215117610.1007/s40262‑017‑0570‑0 28756612
     [Google Scholar]
  25. ŞenyiğitT. SonvicoF. BarbieriS. ÖzerÖ. SantiP. ColomboP. Lecithin/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin.J. Control. Release2010142336837310.1016/j.jconrel.2009.11.013 19932722
     [Google Scholar]
  26. ÖzcanI. AzizoğluE. SenyiğitT. ÖzyazıcıM. ÖzerO. Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations.Int. J. Nanomedicine2013846147510.2147/IJN.S40519 23390364
     [Google Scholar]
  27. MehriziT.Z. ArdestaniM.S. KhamesipourA. HoseiniM.H.M. MosaffaN. AnissianA. RamezaniA. Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major.J. Mater. Sci. Mater. Med.201829812510.1007/s10856‑018‑6122‑9 30056571
     [Google Scholar]
  28. GoyR.C. BrittoD. AssisO.B.G. A review of the antimicrobial activity of chitosan.Polímeros200919324124710.1590/S0104‑14282009000300013
     [Google Scholar]
  29. HeW. GuoX. XiaoL. FengM. Study on the mechanisms of chitosan and its derivatives used as transdermal penetration enhancers.Int. J. Pharm.20093821-223424310.1016/j.ijpharm.2009.07.038 19686826
     [Google Scholar]
/content/journals/cac/10.2174/0115734110314300240723050137
Loading
Preparation and Characterization of Paromomycin Encapsulated in Lecithin-chitosan Nanoparticles for the Topical Treatment of Cutaneous Leishmaniasis
Current Analytical Chemistry 21, 977 (2025); https://doi.org/10.2174/0115734110314300240723050137
/content/journals/cac/10.2174/0115734110314300240723050137
/content/journals/cac/10.2174/0115734110314300240723050137
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): chitosan; cutaneous leishmaniasis; lecithins; Leishmaniasis major; nanoparticles; paromomycin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test